Stock 1177 SINO BIOPHARMACEUTICAL LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

News Sino Biopharmaceutical Limited

Equities

1177

KYG8167W1380

Delayed Hong Kong S.E.
Other stock markets
 07:37:08 03/06/2024 am IST 		5-day change 1st Jan Change
2.84 HKD 0.00% Intraday chart for Sino Biopharmaceutical Limited 0.00% -18.16%
24/05 Sino Biopharmaceutical's Renal Cancer Combination Treatment Shows Promise in Phase III Trials MT
23/05 Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsules for First-Line Treatment of Advanced Renal Cell Carcinoma CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Sino Biopharmaceutical's Renal Cancer Combination Treatment Shows Promise in Phase III Trials
MT
Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsules for First-Line Treatment of Advanced Renal Cell Carcinoma
CI
Sino Biopharmaceutical's Novel Lung Cancer Drug Approved in China; Shares Up 5%
MT
Sino Biopharmaceutical Limited Receives Marketing Approval from National Medical Products Administration of China
CI
Wall Street, Earnings, Federal Reserve Roil Asian Stock Markets
MT
Sino Biopharmaceutical Limited Announces Approval for Marketing of Category 1 Unecritinib Fumarate Capsules
CI
Sino Biopharmaceutical : 2023 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
PU
Sino Biopharm Completes Phase I Study of Hepatitis B Drug
MT
Lull in Geopolitical Tensions Lifts Asian Stock Markets
MT
Hong Kong shares jump on policy support; China slips
RE
Hong Kong shares jump 1.5% on policy support; China slips
RE
Sino Biopharmaceutical Reaches Primary Endpoint for Clinical Research of Myelofibrosis Drug
MT
Sino Biopharmaceutical Limited Announces Category 1 Innovative Drug Rovadicitinib Obtained Positive Results in Key Clinical Research for Registration
CI
Sino Biopharm EBT Buys Back HK$12 Million Worth of Shares
MT
Sino Biopharmaceutical Presents Cancer Drug's Phase-II Clinical Trial Results at AACR 2024
MT
Sino Biopharmaceutical Trustee Repurchases Shares
MT
Sino Biopharmaceutical to Develop Boehringer Ingelheim's Cancer Treatments in China
MT
Sino Biopharmaceutical Limited Enters into Strategic Partnership with Boehringer Ingelheim on Innovative Oncology Portfolio in China
CI
Sino Biopharmaceutical's Attributable Profit Drops 8.3% in 2023
MT
Sino Biopharm (1177.HK) Announces 2023 Annual Results
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 1177 Stock
  4. News Sino Biopharmaceutical Limited